Press Center

Labtec will be present with a team of experts and a booth at both events >>

APR Applied Pharma Research and Labtec announce that the Ondansetron Oral Dispersible Film is now available for licensing in Europe and selected non European countries, after having received marketing authorization. >>

Labtec GmbH has become a fully authorized manufacturer for transdermal drug delivery systems and oral dispersible films with its proprietary RapidFilm® technology. >>

APR Applied Pharma Research and Labtec GmbH Announce Filing for Approval in Europe of Zolmitriptan Oral Dispersible Film (ODF) >>

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. >>

APR Applied Pharma Research s.a. and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film >>

APR Applied Pharma Research and its strategic partner Labtec GmbH announce the successful completion of the pivotal clinical study and its upcoming submission for registration in Europe of their new investigational product Zolmitriptan RapidFilm®. >>

GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec. >>

APR Applied Pharma Research s.a. and Labtec GmbH announce the European Approval of Ondansetron Rapidfilm®, co-developed in partnership with MonoSol Rx and licensed to BioAlliance Pharma SA for EU countries. >>

Active ingredients pass through the skin or dissolve on the tongue >>

Interview with Joachim Suesse, Head of the Business Unit tesa Health Markets >>

SciClone Pharmaceuticals, Inc. and APR Applied Pharma Research S.A. have entered into an exclusive licensing agreement granting SciClone the commercialization rights for APR’s innovative anti-nausea drug Ondansetron Rapidfilm® for China and Vietnam. >>

Abdi Ibrahim Pharmaceuticals and APR Applied Pharma Research SA, together with its joint venture partner Labtec GmbH, have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey. >>

Acquisition of Labtec opens up new line of business for tesa >>

The French company BioAlliance Pharma has submitted an EU marketing application for its RapidFilm oral film-strip formulation of ondansetron. >>

Investment in new segment of the health care sector >>

BioAlliance Pharma S.A., the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, and Applied Pharma Research S.A., together with Labtec GmbH, have entered into an exclusive licensing agreement. >>

APR Applied Pharma Research s.a. and Labtec GmbH announce the successful completion of the pilot bioequivalence study of their Donepezil Rapidfilm® further confirming the validity and adaptability of this innovative proprietary technology. >>

On the basis of bioequivalence assessed in this pivotal study, therapeutic equivalence between Ondansetron Rapidfilm® and Zofran ODT® could successfully be demonstrated. >>